Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566449 · ClinicalTrials.gov registry record · Phase 2
A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT00566449: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00566449 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 32 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566449, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-31001074
Study Locations (20)
Florida
- - Bradenton
- - Fort Myers
- - Orlando
- - South Miami
California
- - Irvine
- - Lafayette
- - San Francisco
North Carolina
- - Chapel Hll
- - Raleigh
Texas
- - Austin
- - Houston
Idaho
- - Eagle
Illinois
- - Libertyville
Kansas
- - Overland Park
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00566449 record still lists
NCT00566449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00566449 names 20 study sites across 13 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00566449 about?
NCT00566449 is a clinical study titled "A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.". The purpose of this study is to evaluate the safety and effectiveness of JNJ-31001074 compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD).
What is the current status of trial NCT00566449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-12. Estimated completion is 2008-07.
What conditions does trial NCT00566449 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00566449?
The interventions under investigation include: Placebo (DRUG), JNJ-31001074 (DRUG).
Who is sponsoring clinical trial NCT00566449?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00566449 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00566449's enrollment target sits among peer trials
32 80th of 102 higher than 23 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia